期刊
LIFE-BASEL
卷 12, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/life12020190
关键词
atherogenesis; atherosclerosis; atherothrombosis; cardiovascular disease; cluster of differentiation 36; myocardial infarction; proprotein convertase subtilisin; kexin type 9; platelet activation
资金
- Directorate of Research and Development, Universitas Indonesia [NKB-631/UN2.RST/HKP.05.00/2021]
Cardiovascular diseases, particularly heart failure caused by myocardial infarction, are the leading cause of death worldwide. Research on atherosclerosis prevention has been conducted to reduce the risk of myocardial infarction. Recent experimental studies have revealed the crucial role of PCSK9 in platelet activation and its involvement in atherosclerosis progression.
Cardiovascular diseases are the leading cause of death worldwide, with the majority of the cases being heart failure due to myocardial infarction. Research on cardiovascular diseases is currently underway, particularly on atherosclerosis prevention, to reduce the risk of myocardial infarction. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been reported to play a role in lipid metabolism, by enhancing low-density lipoprotein (LDL) receptor degradation. Therefore, PCSK9 inhibitors have been developed and found to successfully decrease LDL plasma levels. Recent experimental studies have also implicated PCSK9 in platelet activation, having a key role during atherosclerosis progression. Although numerous studies have addressed the role of PCSK9 role in controlling hypercholesterolemia, studies and discussions exploring its involvement in platelet activation are still limited. Hence, here, we address our current understanding of the pathophysiological process involved in atherosclerosis-induced myocardial infarction (MI) through platelet activation and highlight the molecular mechanisms used by PCSK9 in regulating platelet activation. Undoubtedly, a deeper understanding of the relationship between platelet activation and the underlying molecular mechanisms of PCSK9 in the context of MI progression will provide a new strategy for developing drugs that selectively inhibit the most relevant pathways in cardiovascular disease progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据